Legend Biotech Corp ADR：历史爬坡最快的Car-T疗法，25年继续销售放量-20250317

Investment Rating - The report assigns a "Buy" rating for the company with a target price of $56.0, indicating a potential upside of 47.2$38.05 [4][3]. Core Insights - The company is experiencing rapid growth in its CAR-T therapy, CARVYKTI, with a projected revenue increase of 93% in 2024, reaching $963 million. The total revenue for the company is expected to grow significantly, with estimates of$1.07 billion, $1.70 billion, and$2.35 billion for the years 2025 to 2027 respectively [1][3][5]. - The company is expanding its production capacity, with new facilities in New Jersey and Belgium, and plans to reach an annual production of 10,000 doses by the end of 2025, increasing to 20,000 doses by 2027 [2]. - CARVYKTI is the first CAR-T therapy to demonstrate improved overall survival compared to standard treatment in multiple myeloma, with label updates expected in Europe and the U.S. in 2025 [3]. Financial Summary - The company reported a total revenue of $285 million for 2023, with projections of$627 million for 2024 and $1.068 billion for 2025, reflecting a growth rate of 143.7$518 million in 2023 to a profit of $392 million by 2027, indicating a significant turnaround in profitability [5][6]. - The gross margin is projected to improve from 49% in 2023 to 60% by 2027, while the SG&A expense ratio is expected to decrease from 70% to 23% over the same period [6].